LifeMD Reports Mixed Q4 Results, Guides for Q1 EBITDA Loss Amid Strategic Growth Investments
LFMD sits 36% above its 52-week low of $2.56 on elevated volume (2.2× avg).
Summary
LifeMD reported Q4 revenue below estimates and guided for a Q1 2026 Adjusted EBITDA loss due to strategic growth investments, but highlighted a strong debt-free balance sheet and robust long-term revenue and EBITDA run-rate projections.
Key Events · Earnings and Guidance · LFMD
-
Q4 2025 Revenue Miss
Reported Q4 2025 revenue of $46.9 million, a 4% increase year-over-year, but falling short of analyst estimates.
-
Strong Balance Sheet
Ended 2025 with $36.8 million in cash and no debt, providing significant financial flexibility for growth investments.
-
Q1 2026 Guidance for EBITDA Loss
Forecasts Q1 2026 revenue of $48-$49 million but an Adjusted EBITDA loss of $4-$5 million, attributed to strategic front-loaded patient acquisition investments.
-
Strategic Growth Initiatives
Successfully launched oral Wegovy and expanded women's health offerings, driving record patient sign-ups in Q1.
Analysis · LFMD · Industrial Applications And Services
LifeMD, Inc. reported fourth-quarter revenue that fell short of analyst estimates, and guided for an Adjusted EBITDA loss in Q1 2026 due to significant front-loaded investments in patient acquisition for its weight management (oral Wegovy) and women's health offerings. Despite the short-term profitability dip, the company exited 2025 with a strong balance sheet, including $36.8 million in cash and no debt. Management projects a return to profitability in Q2 2026 and anticipates strong annualized run-rate revenue exceeding $250 million and Adjusted EBITDA over $25 million by Q4 2026, driven by these strategic growth initiatives. Investors should monitor the execution of these growth strategies and the company's ability to achieve its ambitious Q4 2026 run-rate targets.
At the time of this filing, LFMD was trading at $3.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $150.2M. The 52-week trading range was $2.56 to $15.84. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.